Colin Brenan

Colin J.H. Brenan was a serial life sciences entrepreneur who was the CEO of Kibur Medical Inc., a company closing the translational research gap, with a proprietary focus in vivo pathology-driven technology that brings the laboratory to the patient, allowing drug developers to make better choices that accelerate their development programs and clinicians to select therapies that improve patient outcomes. Previously he was Founder/CEO & Director of the single-cell instrumentation company 1CellBio Inc.; formerly Founder/CCO & Director of an antibody-drug developer HiFiBiO Ltd; and Managing Director of the early-stage investor Monsanto Atlas Seed Fund Alliance at Atlas Venture (Cambridge, USA).

Before Atlas, Dr. Brenan was Director of Strategic Relationships at CIMIT, the MGB Healthcare innovation center (Boston, MA). Before CIMIT, Dr. Brenan was the Founder/CTO & Director of BioTrove Inc. (Woburn, USA), commercializing the OpenArrayTM, a nanofluidic PCR array acquired by ThermoFisher Inc., and RapidFireTM, an HT MS prep system acquired by Agilent Inc.

Dr. Brenan was a prolific inventor (26 US patents, 27 ex-US patents), published +50 peer-reviewed articles on diverse topics in biomedical science and technology, and created products with +US$500M in aggregate global sales. He held over a decade of experience in consulting for the NIH and was an active Senior Member of the IEEE EMBS at the time of his passing.

Dr. Brenan held a B.Sc. (Honours Physics), M. Eng. (Electrical), and Ph.D. (Biomedical Engineering) from McGill University (Montreal, Canada) and completed post-doctoral training at MIT (Cambridge, USA).

Colin passed during his term as the 2023-2024 Healthtech Core Team Lead on the 2024 IEEE Entrepreneurship Steering Committee.

He is greatly missed for his humor, service, and dedication in his efforts to advance science and technology for the benefit of humanity.